DXM Distribution Legislation Clears House And Moves To Senate Again
This article was originally published in The Tan Sheet
Executive Summary
Legislation banning distribution of bulk dextromethorphan to people and businesses not registered with FDA passed the House with overwhelming support and moves to the Senate, where similar bills stalled in the two previous sessions
You may also be interested in...
Elections Reshape FDA Oversight Scene On Capitol Hill
The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run
FDA Panel To Weigh DXM Education, Sales Restrictions Against Scheduling
The continued availability of OTC dextromethorphan depends on convincing safety experts that less restrictive measures than scheduling DXM as a controlled substance will sufficiently reduce abuse